# Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness

> **NCT00545675** · PHASE4 · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 146 (estimated)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Abilify(aripiprazole)
- **DRUG:** Depakote (divalproate)

## Key facts

- **NCT ID:** NCT00545675
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2010-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545675, "Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00545675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*